Silexion Therapeutics (SLXN) Competitors $0.82 +0.01 (+1.44%) As of 12:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock SLXN vs. DYAI, FBLG, COEP, KALA, ALXO, ENLV, GBIO, TPST, DARE, and SNYRShould you be buying Silexion Therapeutics stock or one of its competitors? The main competitors of Silexion Therapeutics include Dyadic International (DYAI), FibroBiologics (FBLG), Coeptis Therapeutics (COEP), KALA BIO (KALA), ALX Oncology (ALXO), Enlivex Therapeutics (ENLV), Generation Bio (GBIO), Tempest Therapeutics (TPST), Dare Bioscience (DARE), and Synergy CHC (SNYR). These companies are all part of the "pharmaceutical products" industry. Silexion Therapeutics vs. Its Competitors Dyadic International FibroBiologics Coeptis Therapeutics KALA BIO ALX Oncology Enlivex Therapeutics Generation Bio Tempest Therapeutics Dare Bioscience Synergy CHC Dyadic International (NASDAQ:DYAI) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation. Which has more risk & volatility, DYAI or SLXN? Dyadic International has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Silexion Therapeutics has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500. Which has stronger earnings and valuation, DYAI or SLXN? Dyadic International has higher revenue and earnings than Silexion Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyadic International$3.49M8.03-$5.81M-$0.20-4.66Silexion TherapeuticsN/AN/A-$16.44MN/AN/A Do institutionals & insiders believe in DYAI or SLXN? 28.0% of Dyadic International shares are held by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are held by institutional investors. 29.5% of Dyadic International shares are held by company insiders. Comparatively, 6.0% of Silexion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer DYAI or SLXN? In the previous week, Dyadic International had 2 more articles in the media than Silexion Therapeutics. MarketBeat recorded 2 mentions for Dyadic International and 0 mentions for Silexion Therapeutics. Dyadic International's average media sentiment score of 0.00 equaled Silexion Therapeutics'average media sentiment score. Company Overall Sentiment Dyadic International Neutral Silexion Therapeutics Neutral Is DYAI or SLXN more profitable? Silexion Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -163.94%. Silexion Therapeutics' return on equity of 0.00% beat Dyadic International's return on equity.Company Net Margins Return on Equity Return on Assets Dyadic International-163.94% -233.69% -59.37% Silexion Therapeutics N/A N/A -359.62% Do analysts rate DYAI or SLXN? Dyadic International currently has a consensus target price of $6.00, indicating a potential upside of 544.47%. Silexion Therapeutics has a consensus target price of $5.00, indicating a potential upside of 512.00%. Given Dyadic International's higher possible upside, equities research analysts plainly believe Dyadic International is more favorable than Silexion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Silexion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryDyadic International beats Silexion Therapeutics on 8 of the 10 factors compared between the two stocks. Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLXN vs. The Competition Export to ExcelMetricSilexion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.10M$2.90B$5.50B$9.01BDividend YieldN/A2.64%5.39%4.11%P/E RatioN/A21.5027.4220.07Price / SalesN/A282.64398.50109.13Price / CashN/A41.4736.1356.90Price / Book-0.337.518.015.70Net Income-$16.44M-$55.05M$3.16B$248.47M7 Day Performance0.74%3.05%2.08%2.92%1 Month Performance-14.05%5.80%4.38%5.77%1 Year PerformanceN/A6.15%35.81%21.39% Silexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLXNSilexion TherapeuticsN/A$0.82+1.4%$5.00+512.0%N/A$7.10MN/A0.00N/ADYAIDyadic International2.6223 of 5 stars$0.94+2.9%$6.00+539.7%-35.2%$27.44M$3.49M-4.697News CoverageFBLGFibroBiologics3.0741 of 5 stars$0.72+3.6%$13.00+1,703.3%-85.3%$26.61MN/A-3.4310Positive NewsGap UpCOEPCoeptis Therapeutics0.6129 of 5 stars$7.05-6.7%N/A+36.0%$26.57MN/A-1.222Gap UpKALAKALA BIO3.5891 of 5 stars$4.02-0.5%$13.50+235.8%-24.7%$26.07M$3.89M-0.4930ALXOALX Oncology2.8506 of 5 stars$0.46-5.0%$3.30+617.9%-92.2%$25.84MN/A-0.1940ENLVEnlivex Therapeutics3.3429 of 5 stars$1.16+6.4%$10.00+762.1%-14.4%$25.78MN/A-1.7670GBIOGeneration Bio3.3446 of 5 stars$0.36-5.3%$7.33+1,937.6%-85.6%$25.47M$24.56M-0.33150TPSTTempest Therapeutics1.844 of 5 stars$6.85+1.0%$30.00+338.0%-74.1%$24.97MN/A-0.3820DAREDare Bioscience2.5371 of 5 stars$2.56-9.2%$12.00+368.8%-33.9%$24.96M$10K-15.0630News CoveragePositive NewsHigh Trading VolumeSNYRSynergy CHC3.9609 of 5 stars$2.57-3.0%$10.00+289.1%N/A$24.36M$34.83M0.0040Positive News Related Companies and Tools Related Companies Dyadic International Alternatives FibroBiologics Alternatives Coeptis Therapeutics Alternatives KALA BIO Alternatives ALX Oncology Alternatives Enlivex Therapeutics Alternatives Generation Bio Alternatives Tempest Therapeutics Alternatives Dare Bioscience Alternatives Synergy CHC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLXN) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLXN Stock Alerts